Meeting
2019 ASCO Annual Meeting
Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
Authors
Matthew R. Zibelman
Fox Chase Cancer Center, Philadelphia, PA
Matthew R. Zibelman , Daniel M. Geynisman , Ana M. Molina , Lois Malizzia , Karthik Devarajan , Diana Luong , Elizabeth Sullivan , Michael Anthony Carducci , Elizabeth R. Plimack
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03172754
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4567)
DOI
10.1200/JCO.2019.37.15_suppl.4567
Abstract #
4567
Poster Bd #
393
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC).
First Author: Martin H Voss
Poster
2018 Genitourinary Cancers Symposium
Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study.
First Author: Laurence Albiges
Poster
2014 ASCO Annual Meeting
A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.
First Author: Michael B. Atkins
First Author: Igor Tsaur